New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
06:59 EDTVSTMVerastem data compelling, says Cantor
After Verastem reported data from its Phase Ib combination study of defactinib in combination with docetaxel for the treatment of ovarian cancer, Cantor remains upbeat about the company's overall pipeline. It keeps a $22 price target and Buy rating on the stock.
News For VSTM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 11, 2015
16:38 EDTVSTMVerastem sees sufficient cash to fund operations into 1H17
Subscribe for More Information
16:37 EDTVSTMVerastem sees conducting interim analysis of VS-6063 in Q3
Subscribe for More Information
16:33 EDTVSTMVerastem reports Q1 EPS (46c), consensus (42c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use